ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

Core Insights - Plasma levels of inflammasome ASC are identified as a promising biomarker for early cognitive decline in older adults, particularly those over 60 years old [1][2][5] - ZyVersa Therapeutics is developing Inflammasome ASC Inhibitor IC 100, aimed at inhibiting inflammasome-induced inflammation linked to neurodegenerative diseases [3][6][8] Group 1: Biomarker Findings - Elevated plasma ASC levels were observed in older adults (>60 years) who were cognitively normal at baseline but showed cognitive decline one year later, compared to those who remained cognitively normal [3][4] - The increase in ASC levels was more pronounced in individuals aged 70 years or older, indicating a stronger correlation with early cognitive decline [3][4] - Plasma ASC levels in the cognitive decline group (NI) were higher than those in older adults who were cognitively impaired at both baseline and one year later (II), suggesting ASC levels rise in the early stages of cognitive decline [3][4] Group 2: Diagnostic Power - The area under the curve (AUC) for plasma ASC levels in the NI group versus the NN group for individuals over 70 years old was 0.81, indicating excellent diagnostic capability for differentiating cognitive decline [4] Group 3: Company Overview - ZyVersa Therapeutics is a clinical stage biopharmaceutical company focused on developing first-in-class drugs for inflammatory and renal diseases, with a significant market opportunity exceeding $100 billion [8] - The lead indication for IC 100 is obesity and its associated metabolic complications, with potential applications in various inflammatory diseases [6][8]